Citadel Advisors
MLYS icon

Citadel Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Citadel Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6M Sell
467,598
-132,443
-22% -$3.63M ﹤0.01% 3222
2026
Q1 		$16.3M Buy
600,041
+200,122
+50% +$5.87M ﹤0.01% 2593
2025
Q4 		$14.5M Sell
399,919
-1,667,308
-81% -$66.9M ﹤0.01% 2742
2025
Q3 		$78.4M Buy
2,067,227
+2,052,845
+14,274% +$44.4M 0.01% 1021
2025
Q2 		$195K Sell
14,382
-129,980
-90% -$1.88M ﹤0.01% 10702
2025
Q1 		$2.29M Buy
+144,362
New +$1.66M ﹤0.01% 5280
2024
Q4 		– Sell
-3,136
Closed -$38K – 15053
2024
Q3 		$38K Sell
3,136
-9,898
-76% -$120K ﹤0.01% 12198
2024
Q2 		$152K Buy
13,034
+12,937
+13,337% +$163K ﹤0.01% 10326
2024
Q1 		$1.25K Sell
97
-115,206
-100% -$1.42M ﹤0.01% 14155
2023
Q4 		$992K Buy
115,303
+96,687
+519% +$759K ﹤0.01% 6703
2023
Q3 		$177K Buy
+18,616
New +$243K ﹤0.01% 10113
2023
Q2 		– Sell
-191,048
Closed -$2.99M – 14896
2023
Q1 		$2.99M Buy
+191,048
New +$3.22M ﹤0.01% 4637

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors's MLYS Position: Q2 2026 in Review

Citadel Advisors reduced its Mineralys Therapeutics (MLYS) stake by 22% in Q2 2026, selling an estimated $3.63M and leaving 467,598 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3222.

Citadel Advisors first reported a position in MLYS in Q1 2023 and has held it in 12 quarters since. The position peaked at $78.4M in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Citadel Advisors held 467,598 shares of Mineralys Therapeutics worth $12.6M as of Q2 2026.
  • Citadel Advisors sold 132,443 Mineralys Therapeutics shares in Q2 2026, an estimated $3.63M.
  • Mineralys Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3222 holding.
  • Citadel Advisors first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Citadel Advisors's Mineralys Therapeutics position peaked at $78.4M in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.